Research programme: protease inhibitors - Atea Pharmaceuticals
Latest Information Update: 10 Feb 2023
At a glance
- Originator Atea Pharmaceuticals
- Class Antivirals
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections